Department of Anesthesiology and Perioperative Medicine, the University of Texas MD, Anderson Cancer Center, Houston, TX 77030, USA; Anesthesiology and Surgical Oncology Research Group, Houston, TX 77030, USA.
Anesthesiology and Surgical Oncology Research Group, Houston, TX 77030, USA; Department of Anesthesiology, Massachusetts General Hospital, Harvard University, Boston, MA 02114, USA.
Life Sci. 2021 Aug 1;278:119541. doi: 10.1016/j.lfs.2021.119541. Epub 2021 Apr 27.
In vitro and in vivo studies suggest that the mu-opioid receptor (MOR) is involved in tumorigenesis, and metastasis in cancer. In humans, the use of MOR agonists (opioids) is associated with head and neck squamous cell carcinoma (HNSCC) progression. In the present study, we aimed to examine the role of MOR activation in MOR (+) HNSCC.
FaDu, MDA686Tu and UMSCC47 cell lines were used in in vitro and in vivo experiments. Cells and animals were treated with a highly selective MOR agonist DAMGO, [D-Ala (2), Me Phe (4), Glycol (5)]-enkephalin] or saline 0.9%.
MOR activation significantly increased the proliferation, colony formation, invasion, and migration of FaDu and MDA6868Tu cells and promoted tumor growth in vivo.
These findings suggest that MOR is implicated in tumorigenesis of HNSCC. Overall, our findings identify that MOR could be used as a potential therapeutic target in patients with MOR (+) HNSCC.
体外和体内研究表明，μ-阿片受体（MOR）参与了癌症的发生和转移。在人类中，MOR 激动剂（阿片类药物）的使用与头颈部鳞状细胞癌（HNSCC）的进展有关。在本研究中，我们旨在研究 MOR 激活在 MOR（+）HNSCC 中的作用。
在体外和体内实验中使用了 FaDu、MDA686Tu 和 UMSCC47 细胞系。用高度选择性的 MOR 激动剂 DAMGO（[D-Ala（2），MePhe（4），Glycol（5）]-脑啡肽）或生理盐水 0.9%处理细胞和动物。
MOR 激活显著增加了 FaDu 和 MDA6868Tu 细胞的增殖、集落形成、侵袭和迁移，并促进了体内肿瘤生长。
这些发现表明 MOR 参与了 HNSCC 的肿瘤发生。总的来说，我们的研究结果表明，MOR 可作为 MOR（+）HNSCC 患者的潜在治疗靶点。
